Precision CAR-Tregs for autoimmunity: Engineering tissue-adapted immune regulation

Chimeric antigen receptor regulatory T cells (CAR-Tregs) offer a strategy to concentrate immune regulation within diseased tissues while limiting systemic immunosuppression. Their application to autoimmunity, however, introduces design requirements that differ from those in transplantation. Autoimmune lesions are heterogeneous, dynamic, and often shaped by epitope spreading, inflammatory disruption of Treg identity, and a narrow tolerance for off-target immune suppression. Here, we examine CAR-Treg development through four interconnected design requirements: target architecture, context-dependent function, lineage stability and persistence, and clinical control. Target selection must consider not only antigen specificity, but also native presentation, accessibility, tissue distribution, and the ability to support productive CAR engagement. Functional programming is increasingly extending beyond constitutive suppression toward inducible and locally restricted regulatory outputs. Durable activity further depends on maintaining Treg identity under inflammatory and repeated antigenic challenge, requiring coordinated control of FOXP3 expression, receptor signaling, cytokine support, and tissue fitness. Finally, therapeutic activity cannot be inferred from blood persistence alone; tissue localization, local phenotype, target engagement, manufacturability, and reversibility are integral to the pharmacology of these products. Using type 1 diabetes as a benchmark and drawing on evidence from neuroinflammation, inflammatory bowel disease, antibody-mediated autoimmunity, and early clinical development, we show how different targeting and engineering strategies address distinct biological constraints. The emerging principle is that successful autoimmune CAR-Tregs will depend less on maximizing suppressive potency than on matching recognition, function, stability, and persistence to the biology of the affected tissue.

Authors

Institutions

Publication Details

Journal
Journal of Autoimmunity
Published
2026-11-19
DOI
https://doi.org/10.1016/j.jaut.2026.103661
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Precision CAR-Tregs for autoimmunity: Engineering tissue-adapted immune regulation

Fatih Noyan, Matthias Hardtke‐Wolenski
1 links
Journal of Autoimmunity
CAR-T cell therapy research
article

Precision CAR-Tregs for autoimmunity: Engineering tissue-adapted immune regulation

Fatih Noyan, Matthias Hardtke‐Wolenski
article en

Abstract

Chimeric antigen receptor regulatory T cells (CAR-Tregs) offer a strategy to concentrate immune regulation within diseased tissues while limiting systemic immunosuppression. Their application to autoimmunity, however, introduces design requirements that differ from those in transplantation. Autoimmune lesions are heterogeneous, dynamic, and often shaped by epitope spreading, inflammatory disruption of Treg identity, and a narrow tolerance for off-target immune suppression. Here, we examine CAR-Treg development through four interconnected design requirements: target architecture, context-dependent function, lineage stability and persistence, and clinical control. Target selection must consider not only antigen specificity, but also native presentation, accessibility, tissue distribution, and the ability to support productive CAR engagement. Functional programming is increasingly extending beyond constitutive suppression toward inducible and locally restricted regulatory outputs. Durable activity further depends on maintaining Treg identity under inflammatory and repeated antigenic challenge, requiring coordinated control of FOXP3 expression, receptor signaling, cytokine support, and tissue fitness. Finally, therapeutic activity cannot be inferred from blood persistence alone; tissue localization, local phenotype, target engagement, manufacturability, and reversibility are integral to the pharmacology of these products. Using type 1 diabetes as a benchmark and drawing on evidence from neuroinflammation, inflammatory bowel disease, antibody-mediated autoimmunity, and early clinical development, we show how different targeting and engineering strategies address distinct biological constraints. The emerging principle is that successful autoimmune CAR-Tregs will depend less on maximizing suppressive potency than on matching recognition, function, stability, and persistence to the biology of the affected tissue.

Journal of AutoimmunityVol. 165
Medizinische Hochschule Hannover (DE), Essen University Hospital (DE), University of Duisburg-Essen (DE)
Niedersächsische Ministerium für Wissenschaft und Kultur, Deutsches Zentrum für Lungenforschung
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon